You are viewing Diagnostic center

Firefly Autism opens diagnostic center with no waiting list

COLORADO SPRINGS, Colorado – Current wait lists for an autism diagnosis can go on for years in Colorado. It can be traumatic for people with autism and their families who are in desperate need of help.

“The first signs are that the lack of eye contact when they are young does not progress as a typical child would progress, whether it is language, communication, streaky or repetitive behavior,” said the director. by Firefly South Mandy Rades.

Firefly autism said early childhood intervention is vital in how children with autism navigate this world. They can assess toddlers, children, teens and adults. Firefly Autism in Colorado Springs and Denver offers intensive assessment with no waiting list.

“The research clearly shows that the sooner we can start working with them using applied behavior analysis, the better the results. Radès explained.

There is no blood test, brain scan, or other objective tests that can diagnose autism. Firefly Autism has opened its own diagnostic center with a psychologist on site. The Colorado Springs site opened in June and offers clients one-on-one therapy throughout their session.

“Everything is fully adapted to each particular child,” Rades added. “I think there is not as much stigma as it was 10 years ago and I think there are a lot more resources for families.”


Source link

First-of-its-kind diagnostic center opens in Uganda with life-saving equipment: GE Healthcare and AFRIPHARMA partner to serve communities

GE

GE Healthcare (www.GEHealthcare.in) (NYSE: GEHC) and AFRIPHARMA medical group announce the opening of the Afri-Egypt health services center, the first of its kind in Uganda with life saving equipment from GE Healthcare. The center is located in Jinja and is expected to serve more than 60,000 people in the region, allowing better accessibility to surrounding communities.

The facility is equipped with GE equipment including scanner, digital mammography, x-ray, BMD, ultrasound and life care solutions. These technologies are used in the diagnosis and treatment of various critical illnesses, including in the areas of women’s health, neonatal care, cardiology, internal medicine, HIV, infectious diseases and COVID-19.

This is a regional project between GE Healthcare and AFRIPHARMA that brought together global partners to develop the strategy, design and execution of the facility, including operations and processes, with one goal in mind: better patient care in Uganda, East Africa and East Africa. -Saharan Africa.

Prof Madiha Khattab, CEO of AFRIPHARMA, said: “This state-of-the-art healthcare facility has been built to very high standards with patients in mind despite the harsh environment of the COVID pandemic, along with partners determined to bring domestic treatment to Ugandans and help improve lives ”.

Jennifer Kinyoe, Managing Director of GE Healthcare East Africa, said: “GE Healthcare has been a partner in the region for many decades, through both good and difficult times. This project is an excellent example of how partners and global institutions can respond to critical local needs in Uganda. With this innovative facility, access across the country is improved, we are helping clinicians get an early diagnosis and lives will be saved. This supports our strategy in Africa to bring the best health services to patients, helping doctors and practitioners diagnose, treat and save lives.

Distributed by APO Group on behalf of GE.

About GE Healthcare:
GE Healthcare is GE’s $ 19.8 billion healthcare business (NYSE: GE). As a leading provider of medical imaging, surveillance, bioproduction, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through smart devices, data analytics , applications and services. With more than 100 years of experience in the healthcare industry and more than 50,000 employees worldwide, the company helps improve outcomes more effectively for patients, healthcare providers, researchers and businesses. life sciences from around the world.

© Press release 2021


Source link

First-of-its-kind diagnostic center opens in Uganda with life-saving equipment: GE Healthcare and AFRIPHARMA partner to serve communities

GE Healthcare (www.GEHealthcare.in) (NYSE: GEHC) and medical group AFRIPHARMA announce the opening of the Afri-Egypt Health Services Center, the first of its kind in Uganda with life saving equipment from GE Healthcare. The center is located in Jinja and is expected to serve more than 60,000 people in the region, allowing better accessibility to surrounding communities.

The facility is equipped with GE equipment, including a computed tomography machine, digital mammography, x-ray, BMD, Ultrasound and life care solutions. These technologies are used in the diagnosis and treatment of various serious diseases, especially in the fields of women’s health, neonatal care, cardiology, internal medicine, HIV, infectious diseases and COVID-19.

This is a regional project between GE Healthcare and AFRIPHARMA which brought together global partners to develop the strategy, design and execution of the facility, including operations and processes, with one goal in mind: better patient care in Uganda, East Africa and in sub-Saharan Africa.

Professor Madiha Khattab, CEO AFRIPHARMA said: “This state-of-the-art healthcare facility has been built to very high standards with patients in mind despite the harsh environment of the hospital. COVID pandemic, with partners determined to bring domestic treatment to Ugandans and help improve lives ”.

Jennifer Kinyoe, Managing Director of GE Healthcare East Africa, said: “GE Healthcare has been a partner in the region for many decades, through both good and difficult times. This project is a prime example of how partners and global institutions can respond to critical local needs in Uganda. With this innovative facility, access across the country is improved, we are helping clinicians get an early diagnosis and lives will be saved. This supports our strategy in Africa to bring the best health services to patients, helping doctors and practitioners diagnose, treat and save lives. ”

Distributed by APO Group on behalf of GE.

About GE Healthcare:
GE Healthcare is GE’s $ 19.8 billion healthcare business (NYSE: GE). As a leading provider of medical imaging, surveillance, bioproduction, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through smart devices, data analytics , applications and services. With more than 100 years of experience in the healthcare industry and more than 50,000 employees worldwide, the company helps improve outcomes more effectively for patients, healthcare providers, researchers and businesses. life sciences from around the world.

Media files

Download logo

The first diagnostic center of its kind opens in Uganda with life-saving equipment: GE Healthcare & AFRIPHARMA partner in the service of communities
GE

Africanews provides APO Group content as a service to its readers, but does not edit the articles it publishes.


Source link

Vijaya diagnostic center makes mixed debut, posts 2% premium on BSE and ESN

At 10:10 am, shares of Vijaya Diagnostic were trading 8.8% higher against BSE

Shares of Vijaya Diagnostic Center made a mixed debut on the stock exchanges. The shares of the diagnostic chain supported by Kedaara Capital listed at Rs 542.30 on BSE, a premium of 2.13% over the issue price of Rs 531 per share. On the NSE, shares opened at Rs 540, a premium of 1.69%. At 10:10 am, shares of Vijaya Diagnostic were trading at Rs 577, up 8.8%, on BSE and at Rs 576.25, up 8.5%, on BSE.

The public offering of Vijaya Diagnostic Center was entirely an offer to sell 35.69 million shares by existing shareholders and promoters, including Dr S Surenranath Reddy, Karakoram and Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF I.

The public offering was subscribed 4.54 times. The segment of qualified institutional buyers was subscribed 13.07 times, non-institutional investors were subscribed 1.32 times and the share of retail investors was subscribed 1.09 times.

The Vijaya Diagnostic Center was promoted by Dr S Surendranath Reddy. It is one of the largest integrated diagnostic chains in South India, offering pathology and radiology testing services in 80 diagnostic centers and 11 reference laboratories in 13 towns and villages in Telangana, Andhra Pradesh. , NCR and Kolkata.

Edelweiss Financial Services, ICICI Securities, and Kotak Mahindra Capital are the primary maintainers of the public issue, while KFintech is the registrar of the issue.


Source link

The initial public offering (IPO) of Vijaya Diagnostic opens for subscription today, i.e. September 1 and will close on September 3

Vijaya Diagnostic IPO: Vijaya Diagnostic Center shares are expected to be listed on September 14.

The initial public offering (IPO) of Rs 1,895.04 crore from Vijaya Diagnostic Center opens for subscription today, i.e. September 1 and will close on September 3. The initial public offering of diagnostic chain Kedaara Capital is entirely an offer to sell 35.69 million shares by existing shareholders. The shares will be sold in the price range of Rs 522 to Rs 531 per share and are expected to be listed on September 14.

Bidders may bid on the public issue of the for a lot of 28 shares and in multiples thereof, up to 13 lots. About 50 percent of the shares offered will be reserved for Qualified Institutional Buyers (QIB), 15 percent for Non-Institutional Investors (NII) and 35 percent for Retail Investors.

Vijaya Diagnostic will not receive any funds from the IPO as it is entirely an offer to sell.

The Vijaya Diagnostic Center, promoted by Dr S Surendranath Reddy, is one of the largest integrated diagnostic chains in South India. It offers pathology and radiology testing services in 80 diagnostic centers and 11 reference laboratories in Telangana, Andhra Pradesh, NCR and Kolkata.

Edelweiss Financial Services, ICICI Securities and Kotak Mahindra Capital will be primarily responsible for the issuance, while KFintech will be the registrar.


Source link

What you need to know – Vijaya Diagnostic Center Limited IPO

Here is an important thing to know about the IPO of Vijaya Diagnostic Center Limited:

1) The issue: The initial public offer includes an offer to sell a maximum of 35,688,064 participating shares by the selling shareholders. The issue will have a price range of Rs 522 to Rs 531 per share of par value of Re1 each (“Participating Shares”).

2) Largest Integrated Diagnostics Player: The Company is the largest integrated diagnostics chain that combines pathology and radiology services in South India, in terms of operating revenue. It is also one of the fastest growing diagnostic chains in terms of turnover for the 2020 financial year (Source: CRISIL report).

3) Comprehensive service offerings: The Company offers a comprehensive range of approximately 740 routine tests and 870 specialized pathology tests and approximately 220 basic radiology tests and 320 advanced radiology tests which cover a range of specialties and disciplines, as of June 30, 2021.

4) Vast operational network: the Company has built a vast operational network consisting of 81 diagnostic centers and 11 co-located reference laboratories, in 13 towns and villages in the states of Telangana and Andhra Pradesh and in the national capital region. and Kolkata, as of June 30, 2021

5) Growth strategy:

Deepen Penetration and Broaden Customer Base: To deepen its penetration and increase its customer base to consolidate its leadership position in its core market, the plan includes:

o Expand the service network by opening additional diagnostic centers;

o Improve the capacity of its laboratory and its test menu by adding the latest technologies;

o Increase its activity with individual customers by offering a portfolio of additional services;

o Physician engagement through medical awareness initiatives and meetings with practicing physicians; and

o Increased emphasis on prevention and wellness offers.

Expansion of the network: the Company will continue to focus on expanding its network by creating departments and hubs in the existing watershed, adding reference laboratories and increasing its home collection services in the main geographic areas.

Focus on customer-centric service offerings: the company intends to offer additional prevention and wellness services, adopt new cutting-edge diagnostic testing technology, and create customized packages for its customers.

6) Expansion plan: plans to expand its presence in key towns and villages identified in the adjacent geographic areas of Telangana and Andhra Pradesh and in eastern India, particularly Kolkata.

7) Selective Acquisition: The Company plans to complement its organic growth through selective acquisitions / strategic partnerships with brands with a strong vintage and market position in adjacent markets.

8) High brand recall: The company has high brand recall, resulting in high share of individual consumer activity and customer loyalty. The company’s focus on the consumer and, combined with its brand recognition for quality diagnostic services, results in higher brand recall in its key geographies and allows us to have a share high number of walk-in clients.

9) Strong Technical Capabilities: The company has strong technical capabilities, quality infrastructure and advanced medical technology with strong IT infrastructure.

· The operations of the diagnostic center are supported by a centralized front-end IT platform.

As of June 30, 2021, the company’s radiological testing operations are supported by radiology equipment comprising 15 CT machines, 18 MRI machines and five PET CT / Gamma machines, and a team of 105 radiologists in the centers of diagnostic

10) Strong Industry Growth Prospects: According to CRISIL report, India diagnostics market is expected to grow at a CAGR of around 12% to 13% to reach around Rs. 920 billion to Rs. 980 billion by l ‘fiscal year 2023 from Rs. 710 billion to Rs. 730 billion in fiscal year 2021

· The diagnostics market in Telangana and Andhra Pradesh, the states in which the company has a significant presence, is expected to reach around Rs. 120 billion currently to Rs. 130 billion by fiscal year 2023.

The main drivers of the Indian diagnostics market include (i) increasing health awareness and disposable income, (ii) increasing demand for better health facilities as well as quality of care of individuals , and (iii) increased expenditure on prevention and well-being.

11) Robust financial performance: As of June 30, 2021, the company recorded total income of Rs. 125.97 crore. For fiscal year 2021, the company’s total income was Rs. 388.59 crore.

The company’s OPBDIT margin ranked second among other major diagnostic players during fiscal year 2021

For fiscal 2020, the average test per customer was 2.8, operating revenue per customer was Rs. 1214 and OPBDIT per customer was Rs. 475 which is higher than the peers listed according to the CRISIL report.

· For fiscal year 2021, the company’s RONW was 23.64% and the ROCE (before cash) was 42%.


Source link

Vijaya Diagnostic Center IPO fixes price range of 522 to 531 per share

MUMBAI: Vijaya Diagnostic Center Ltd, backed by Kedaara Capital, set the price range for its initial public offering (IPO) at ??522-531 an action. Previously, the company announced that its IPO would open on September 1 and close on September 3.

The IPO consists of a pure sell offer (OFS) of 35.69 million shares by its existing shareholders and promoters. OFS includes up to 5.1 million shares by Dr S Surenranath Reddy, up to 29.49 million shares by Karakoram Ltd, 1.10 million shares by Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF I.

On the price of the upper band, the company plans to increase ??1,895.14 crores. The company is expected to go public on September 14.

ICICI Securities, Edelweiss Financial Services and Kotak Mahindra Capital Co Ltd are the main managers of the issue.

For the 2021 financial year, the company achieved a turnover of ??376.75 crore compared to ??338.82 crores a year ago. The net profit for the year amounts to ??84.91 crores compared to ??62.51 crore a year ago.

The company’s bank balance is ??200.11 crore, significantly higher than the outstanding debt of ??4.47 crore in March 2021.

Vijaya Diagnostic is South India’s largest integrated diagnostic chain by operating revenue, and also one of the fastest growing diagnostic chains by revenue for the fiscal year 2020. It offers a one-stop solution for pathology and radiology testing services to our customers through our extensive operational network, which includes 80 diagnostic centers and 11 reference laboratories in 13 towns and villages in the states of Telangana and Andhra Pradesh, as well as in the National Capital Region and Kolkata.

The practice offers a full range of approximately 740 routine tests and 870 specialist pathology tests and approximately 220 basic radiology tests and 320 advanced radiology tests that cover a range of specialties and disciplines, as of March 2021.

To subscribe to Mint newsletters

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our app now !!


Source link

Shields MRI Framingham honored as Center of Excellence in Diagnostics by American College of Radiology – Framingham SOURCE

FRAMINGHAM – Shields Health Care Group announced today that its MRI facility in Framingham has been recognized as a Center of Excellence in Diagnostic Imaging® (DICOE) by the American College of Radiology (ACR).

It is the first Shields MRI center to achieve this prestigious designation and one of the few outpatient diagnostic imaging centers in New England to achieve this prestigious designation.

The DICOE program, which represents the pinnacle of medical imaging care, is an achievement that goes beyond accreditation to recognize best practices in imaging and diagnostic care. This includes a comprehensive assessment of the entire medical imaging business, including structure and results.

The Center of Excellence in Diagnostic Imaging® (DICOE) designation recognizes excellence at many levels, including professional staff, technology and the policies and procedures followed by the organization, as well as superior patient care.

In order to receive this elite distinction, establishments must be accredited by the ACR in all the modalities they offer and in which the ACR offers an accreditation program. Another requirement is participation in the Dose Index Registry® and General Radiology Improvement Database, as well as Image Wisely® and Image Gently®. Shields MRI Framingham underwent a full inspection by a national team, citing the shields as “truly deserving of this seal” early in the process.

As a DICOE facility, Shields MRI Framingham:

  • Provides patients with the utmost confidence to receive today’s highest levels of imaging quality, safety and care;
  • Offers excellence at many levels – professional staff, technology, policies and procedures;
  • Obtained accreditation from the American College of Radiology in all imaging modalities we offer;
  • Has exceeded standard accreditation requirements for the American College of Radiology Center of Excellence in Diagnostic Imaging designation;
  • Has an ongoing self-assessment (and improvement) process, including participation in the ACR Dose Index® registry and general radiology improvement database.

“Shields takes great pride in providing the highest quality diagnostic services while fostering a positive patient experience. This distinction from the ACR is therefore a goal that we are delighted to achieve, ”said Peter Ferrari, President of Shields Health Care Group. “Our Framingham team, Shields clinical advisors and our Quality and Safety Committee which led this initiative, have devoted months of hard work to providing care to our patients, demonstrating our commitment to quality. We look forward to continuing this honor throughout our network over the next several years. “

Shields MRI Framingham is located at 14 Cochituate Road in Framingham.

***

In full transparency, the press release and photos have been submitted to SOURCE media for publication.


Source link

NMSU autism diagnostic center open for telehealth appointments

As the pandemic delayed the physical opening of New Mexico State University’s new autism diagnostic center, the center now offers telehealth services to children under 36 months in need of diagnostic evaluation of autism spectrum disorders.

In order to receive treatment, a child must have a medical diagnosis of ASD from a qualified assessment provider. Since the center opened last year, staff have seen strong demand from parents and children, not just from southern New Mexico, but across the state.

While there are several providers of autism assessment, the state’s only other diagnostic center is located at the University of New Mexico, and there is a wait of up to two years for a diagnostic evaluation. Such a long wait could lead to delayed access to necessary interventional services, an increase in the cost of lifelong care and less favorable outcomes.

The evaluations are currently being carried out by Dr Cosette Montañez who leads the interdisciplinary team at ADC. She is a registered psychologist and NMSU Associate Professor in the Department of Communication Disorders. She is also a Stage 1 Applied Behavior Analysis Stage 1 Autism Assessment Practitioner and Board Certified Behavior Analyst.

“We have received referrals from 13 counties, including as far away as Farmington,” Montañez said. “There is such a long wait everywhere, and the pool of diagnostic assessment providers in the state is very limited.”

Montañez has over 15 years of experience performing school and clinical assessments for autism and other neurodevelopmental disorders with children aged 18 months to 17 years. In addition to her degrees and academic training experience, she is bilingual in English and Spanish and is able to work and support people in both languages.

Montañez said the current telehealth process has made it easier for parents to submit documents and conduct interviews online. The CDA will more than likely adopt some of these procedures when the center begins to accept in-person appointments.

A safety plan has been submitted to the NMSU for a return to campus, but no timeline has yet been determined, Montañez said. There are also plans to hire additional staff, including a clinical psychologist, a social worker and an administrative assistant.

The Communication Disorders Department led the project, working closely with former State Senator Mary Kay Papen and NMSU Senior Director of Government Affairs Ricardo Rel to secure funding.

For more information, call the Autism Diagnostic Center at 575-646-3177.

Author: Adriana M. Chavez – NMSU

***

For updates on all the news around Las Cruces and Southern New Mexico, please visit our press partners at Las Cruces Today


Source link

Abu Dhabi University forges strategic partnership with Advanced Cure Diagnostic Center

  • The MoU aims to promote the links between the two institutions through student internships, training programs, sharing of facilities and resources and exchange of knowledge.
  • Abu Dhabi University and the Advanced Cure Diagnostic Center will cooperate in the areas of counseling, academic studies, institutional support and development, and research and development.

Abu Dhabi: Abu Dhabi University (ADU) has entered into a strategic partnership with Advanced Cure Diagnostic Center (ACDC), following the signing by both parties of a Memorandum of Understanding (MoU). Founded in 2007 as a comprehensive ambulatory care unit with over a dozen specialties, ACDC is home to leading physicians in a variety of medical fields.

The MoU aims to promote the links between the two institutions through student internships, training programs, sharing of facilities and resources and exchange of knowledge. The deal will see the two sides cooperate to mutually benefit from advice, academic studies, institutional support and development, and research and development.

Joint research and academic activities are some of the key areas in which the two institutions are ready to work together, in addition to the exchange of students and faculty members. The two institutions seek to expand their exchanges of educational, cultural and administrative material, through various academic programs.

Commenting on the agreement, Professor Wassim Y. Almawi of ADU, said: “We are delighted to enter into this strategic partnership with Advanced Cure Diagnostic Center, which reflects our commitment to work collaboratively with leading institutions in the academic, health and research fields. Our aim is to provide our students with the crucial training and transferable skills they need to succeed as future healthcare professionals and meet the needs of the healthcare sector of Abu Dhabi, UAE, CCG and beyond.

He added, “This agreement will pave the way, providing a sustainable environment that encourages creativity and innovation and the development of scientific research, community engagement, as well as the dissemination of knowledge between Abu Dhabi University and the Advanced Cure Diagnostic Center. We are optimistic that this collaboration will be fruitful in the fields of research and professional development and we look forward to working together successfully. “

As per the agreement, ADU offers its pedagogical expertise and faculty to deliver lectures and training workshops to strengthen the role of human resources and administrative and leadership practices at ACDC.

Additionally, ADU will have access to the medical diagnostic laboratories and educational expertise of ACDC, to train ADU students in the areas of diagnostic medicine, nutrition technology and dietetics and others. .

ADU and ACDC will work together to facilitate information exchange and networking between students, faculty and staff, by organizing conferences, workshops, seminars, academic and training programs, in order to present the latest developments and best practices in areas of common interest.

For more information, please visit: www.adu.ac.ae

Ends

About Abu Dhabi University:

Established in 2003, the University of Abu Dhabi (ADU) is the largest private university in the United Arab Emirates. With campuses in Abu Dhabi, Dubai, Al Ain and Al Dhafra, the university has a total enrollment of 7,800 students of over 80 nationalities. Structured into colleges of arts and sciences, business, engineering, law, and health sciences, ADU offers undergraduate and graduate programs in a wide range of disciplines.

Abu Dhabi University is recognized as a world-class institution dedicated to excellence in teaching, research and student experience, as evidenced by its prestigious regional and international accreditations. The University was the first private higher education institution in the CCG to achieve international accreditation from the Californian Western Association of Schools and Colleges (WASC). ADU’s College of Business is accredited by the Association to Advance Collegiate Schools of Business (AACSB) and the prestigious EFMD Quality Improvement System (EQUIS). At the program level, the College of Engineering has received international accreditation from the world-renowned Accreditation Board for Engineering and Technology (ABET), and the Bachelor of Architecture has received Part 1 validation from the Royal Institute of British Architects (RIBA). The College of Health Sciences has obtained accreditation from the Agency for Accreditation of Public Health Education (APHEA).

According to the 2021 QS World University ranking, Abu Dhabi University ranks among the top 750 universities in the world and among the top 150 universities in the world under the age of 50. ADU also secured a top 3 place in the world for international faculty and maintained its long standing position among the top 11 universities globally recognized for the diversity of their student body.

Media contacts
Weber Shandwick for Abu Dhabi University
Ghada El Makadma
[email protected]
+971 2 449 4457

© Press release 2021


Source link